Datanomics: India doubles its share in prescription drugs to the United States (US)
- IBEF
- September 30, 2025
In FY25, nearly 35% of India’s pharmaceutical exports were destined for the United States (US), with industry estimates indicating that over 95% of these shipments comprised generic drugs, while the remainder were branded or patented products. The latter now face 100% tariffs in the US, which could affect larger Indian pharmaceutical firms; however, generic drug manufacturers are expected to remain largely unaffected. Indian generics have steadily increased their presence in the US market, with their share of total prescription drugs rising from approximately 21% in 2013 to 42% in 2022, while contributions from other countries nearly halved over the same period.
Major Indian pharmaceutical companies continue to derive significant revenues from the US market. In FY25, Gland Pharma, Aurobindo Pharma, and Dr. Reddy’s Laboratories earned 54%, 47%, and 45% of their consolidated revenues, respectively, from the US. In 2022, 90% of total drugs prescribed in the US were unbranded generics, whereas branded drugs accounted for just 10% of prescriptions but represented 92% of the total sales value. This underscores the strong foothold of Indian generics in the US while highlighting potential exposure for firms reliant on patented and branded products.
Disclaimer: This information has been collected through secondary research and IBEF is not responsible for any errors in the same.
Partners
